182 related articles for article (PubMed ID: 10232594)
21. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3.
Chatenoud L; Baudrihaye MF; Chkoff N; Kreis H; Goldstein G; Bach JF
J Immunol; 1986 Aug; 137(3):830-8. PubMed ID: 3487589
[TBL] [Abstract][Full Text] [Related]
22. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
Parlevliet KJ; ten Berge IJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
J Clin Invest; 1994 Jun; 93(6):2519-25. PubMed ID: 8200988
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
24. Immunologic monitoring during OKT3 therapy.
Chatenoud L
Clin Transplant; 1993 Aug; 7(4 Pt 2):422-30. PubMed ID: 10146352
[TBL] [Abstract][Full Text] [Related]
25. Selective immunosuppression with anti-T cell monoclonal antibodies.
Chatenoud L; Bach JF
Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
27. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
[TBL] [Abstract][Full Text] [Related]
29. Differential responses of invariant V alpha 24J alpha Q T cells and MHC class II-restricted CD4+ T cells to dexamethasone.
Milner JD; Kent SC; Ashley TA; Wilson SB; Strominger JL; Hafler DA
J Immunol; 1999 Sep; 163(5):2522-9. PubMed ID: 10452989
[TBL] [Abstract][Full Text] [Related]
30. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
31. In vitro characterization of five humanized OKT3 effector function variant antibodies.
Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA
Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
[TBL] [Abstract][Full Text] [Related]
33. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
35. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
Chatenoud L
Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
37. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
[TBL] [Abstract][Full Text] [Related]
38. Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response.
Madden RL; Schroeder TJ; Alexander JW; First MR
Transplant Sci; 1994 Sep; 4(1):111-4. PubMed ID: 7804689
[No Abstract] [Full Text] [Related]
39. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
40. [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody].
Zhu HL; Li Y; Chang XH; Cui H; Feng J; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):52-6. PubMed ID: 16635330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]